Note: This is NOT an IPO. This is an uplisting to the NYSE-AmEx – also known as the NYSE-American Exchange – from the OTC market. Devonian Health’s stock also trades on the TSX Venture Exchange in Toronto. This is a unit offering of stock and warrants.

(Incorporated in Canada)

Devonian Health Group is pioneering a new generation of botanical drugs designed to safely and effectively treat inflammatory and fibrotic diseases. These are multi-billion-dollar global markets dominated by costly biologics and immunosuppressants that often present safety and tolerability challenges. Devonian’s approach harnesses the therapeutic power of plant-based active compounds to offer safer, more accessible, and differentiated treatment options.

Thykamine™, the company’s proprietary first-in-class anti-inflammatory molecule, has demonstrated efficacy signals in both preclinical and early clinical studies and was well tolerated. With antioxidant and immunomodulatory properties, Thykamine™ represents a novel therapeutic approach for conditions driven by inflammation and oxidative stress.

Devonian is advancing Thykamine™ into clinical Phase 2/3 development for atopic dermatitis in the pediatric patient population and radiodermatitis, a condition associated with radiation treatment for cancer  — two indications with significant unmet medical needs and commercial potential.

Note: Net loss and revenue are in U.S. dollars for the year that ended on July 31, 2025. 

(Note: Devonian Health Group Inc. disclosed the terms for its small public offering – an uplisting – in an F-1/A filing dated Sept 2, 2026: 3.07 million common units at a price range of $6.00 to $8.00 to raise $21.49 million, if priced at the $7.00 mid-point of its range. Each unit consists of one share of common stock and one warrant to buy one share.)